← Leaderboards
John R Ohlfest
Discovery Genomics, Inc.
$2,347,828
Attributed
$3,112,566
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $990.4K · FY2006–14$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,112,566 · 6
By mechanism
R01$2,150,203 · 3
R21$724,485 · 2
R41$237,878 · 1
Top collaborators
- William F Elmquist5 shared
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelBrain NeoplasmsNeoplastic CellBaseTumorCellsGliomaResponseClinical TrialsOperative Surgical ProceduresGlioblastomaMalignant Neoplasm Of BrainAnimalsIn VivoResearch StudyAntigensGeneticGene TransferExcisionExhibitsAnimal ModelImmunotherapyBrainImmune Response
Grant awards (13)
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$297,944
R01 · FY2014 · CA
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$288,640
R01 · FY2013 · CA
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$306,972
R01 · FY2012 · CA
Oxygen as a master immunologic switch$313,325
R01 · FY2011 · CA · contact PI
Discovery and Validation of Tumor Immunoevasion Mechanisms$307,402
R01 · FY2011 · CA · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$306,884
R01 · FY2011 · CA
Understanding and enhancing mechanisms of priming in cancer immunotherapy$62,750
R21 · FY2011 · NS · contact PI
Improving Delivery of Molecularly-Targeted Therapy to Invasive Glioma Cells$329,036
R01 · FY2010 · CA
Understanding and enhancing mechanisms of priming in cancer immunotherapy$302,000
R21 · FY2010 · NS · contact PI
Concurrent Immune Stimulation and Inhibition of Angiogenesis for Glioma Therapy$163,516
R21 · FY2008 · NS · contact PI
Concurrent Immune Stimulation and Inhibition of Angiogenesis for Glioma Therapy$196,219
R21 · FY2007 · NS · contact PI
Brain Tumor Stem Cell-targeted Gene Therapy$74,296
R41 · FY2007 · CA · contact PI
Brain Tumor Stem Cell-targeted Gene Therapy$163,582
R41 · FY2006 · CA · contact PI